The objective of this report is to perform a systematic review of the beneficial and harmful effects of adalimumab via subcutaneous injection at recommended doses for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy or who are intolerant to such therapies.
[Table: see text]
Copyright © 2016 Canadian Agency for Drugs and Technologies in Health.